Irinotecan HCl Trihydrate

別名：CPT-11 HCl Trihydrate

製品コード：S2217 純度：99.97%

Irinotecan HCl Trihydrate is a hydrochloride trihydrate of irinotecan (Camptosar, Campto, CPT-11) which is a topoisomerase I inhibitor with IC50 of 15.8 and 5.17 μM for LoVo cells and HT-29 cells, respectively.

CAS No. 136572-09-3

サイズ	価格(税別)	在庫状況
10mM (1mL in DMSO)	JPY 28500	国内在庫あり
5mg	JPY 22000	国内在庫あり
25mg	JPY 44500	国内在庫あり
100mg	JPY 79300	国内在庫あり
1g	JPY 145500	国内在庫なし(納期7~10日)

代表番号: 045-509-1970\|電子メール：[email protected] よく尋ねられる質問

文献中Selleckの製品使用例（87）

製品安全説明書

現在のバッチを見る：純度： 99.97%

99.97

Irinotecan HCl Trihydrate関連製品

関連ターゲット	Topo I Topo II Topo IV	もっと見る
関連製品	Betulinic acid (S)-10-Hydroxycamptothecin Beta-Lapachone Amonafide Voreloxin (SNS-595) hydrochloride Ellagic acid Genz-644282 Hydroxy Camptothecine Rubitecan	もっと見る
関連化合物ライブラリー	FDA-approved Drug Library Natural Product Library Apoptosis Compound Library DNA Damage/DNA Repair compound Library Cell Cycle compound library	もっと見る

シグナル伝達経路

Topoisomeraseシグナル伝達経路

Topoisomerase阻害剤の選択性比較

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	活性情報	PMID
HEK293	Inhibition of human	up to 500 uM	1.5 mins	Inhibition of human MATE2K-mediated ASP+ uptake expressed in HEK293 cells up to 500 uM after 1.5 mins by fluorescence assay, IC50 = 7.9 μM.	23241029
MM487	Antiproliferative assay	10 uM	72 hrs	Antiproliferative activity against human MM487 cells at 10 uM after 72 hrs by MTT assay relative to control, IC50 = 9.4 μM.	29150335
MM432	Antiproliferative assay	10 uM	72 hrs	Antiproliferative activity against human MM432 cells at 10 uM after 72 hrs by MTT assay relative to control, IC50 = 10 μM.	29150335
HT-29	Antitumor assay	60 mg/kg	2 days	Antitumor activity against human HT-29 cells xenografted in nude mouse assessed as tumor growth inhibition at 60 mg/kg, iv tid administered 2 days measured on day 20	23360284
BT-483	Function assay	1 uM	24 hrs	Induction of DNA damage in human BT-483 cells assessed as gamma H2AX phosphorylation at Ser139 at 1 uM after 24 hrs by Western blot analysis	23419737
HCT116	Antitumor assay	30 mg/kg	6 days	Antitumor activity against human HCT116 cells xenografted in nude mouse assessed as survival at 30 mg/kg,iv qd administered for 6 days	24583355
H3347	Antitumor assay	30 mg/kg	6 days	Antitumor activity against human H3347 cells xenografted in nude mouse assessed as survival at 30 mg/kg,iv qd administered for 6 days	24583355
SW620	Antitumor assay	12.5 mg/kg		Antitumor activity against human SW620 cells xenografted in nude SCID mouse assessed as delay in tumor growth at 12.5 mg/kg, ip	22111927
HCT116	Antitumor assay	100 mg/kg		Antitumor activity against human HCT116 cells xenografted in nu/nu mouse assessed as tumor regression at 100 mg/kg, iv dosed once every week	25003995
NCI-H526	Antitumor assay	30 mg/kg		Antitumor activity against human NCI-H526 cells xenografted in athymic nude mouse at 30 mg/kg, iv qd administered 5 times for every 2 days	28064078
A375	Cytotoxicity assay		72 hrs	Cytotoxicity against human A375 cells after 72 hrs by alamar blue assay, IC50 = 0.004 μM.	21341674
MDA-MB-435	Cytotoxicity assay		3 days	Cytotoxicity against human MDA-MB-435 cells after 3 days by MTT assay, IC50 = 17 μM.	20942490
LoVo	Cytotoxicity assay		3 days	Cytotoxicity against human LoVo cells after 3 days by MTT assay, IC50 = 8.8 μM.	20942490
A549	Cytotoxicity assay		3 days	Cytotoxicity against human A549 cells after 3 days by MTT assay, IC50 = 6.4 μM.	20942490
LoVo	Cytotoxicity assay		72 hrs	Cytotoxicity against human LoVo cells after 72 hrs by MTT assay, IC50 = 4.99 μM.	20371183
A549	Cytotoxicity assay		72 hrs	Cytotoxicity against human A549 cells after 72 hrs by MTT assay, IC50 = 4.61 μM.	20371183
MDA-MB-435	Cytotoxicity assay		72 hrs	Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay, IC50 = 1.14 μM.	20371183
LS174T	Cytotoxicity assay		96 hrs	Cytotoxicity against human LS174T cells after 96 hrs by MTT assay, IC50 = 1.16 μM.	18513976
MCF7	Antitumor assay		4 hrs	Antitumor activity against human MCF7 cells after 4 hrs by MTT assay, IC50 = 17.403 μM.	18207748
LOVO	Antitumor assay		4 hrs	Antitumor activity against human LOVO cells after 4 hrs by MTT assay, IC50 = 9.015 μM.	18207748
A549	Antitumor assay		4 hrs	Antitumor activity against human A549 cells after 4 hrs by MTT assay, IC50 = 6.528 μM.	18207748
K562	Antiproliferative assay		72 hrs	Antiproliferative activity against human K562 cells after 72 hrs, GI50 = 1.9 μM.	25420175
MDA-MB-435	Cytotoxicity assay		72 hrs	Cytotoxicity against human MDA-MB-435 cells incubated for 72 hrs by MTT assay, GI50 = 12.2 μM.	22867019
HCT116	Cytotoxicity assay		72 hrs	Cytotoxicity against human HCT116 cells incubated for 72 hrs by MTT assay, GI50 = 7.1 μM.	22867019
A549	Cytotoxicity assay		72 hrs	Cytotoxicity against human A549 cells incubated for 72 hrs by MTT assay, GI50 = 5 μM.	22867019
MDA-MB-231	Growth inhibition assay		72 hrs	Growth inhibition of human MDA-MB-231 cells after 72 hrs by XTT assay, GI50 = 9.17 μM.	22079254
HepG2	Growth inhibition assay		72 hrs	Growth inhibition of human HepG2 cells after 72 hrs by XTT assay, GI50 = 5.94 μM.	22079254
Hep3B	Growth inhibition assay		72 hrs	Growth inhibition of human Hep3B cells after 72 hrs by XTT assay, GI50 = 4.73 μM.	22079254
HepG2	Antiproliferative assay		72 hrs	Antiproliferative activity against human HepG2 cells after 72 hrs by XTT assay, GI50 = 5.94 μM.	19796956
Hep3B	Antiproliferative assay		72 hrs	Antiproliferative activity against human Hep3B cells after 72 hrs by XTT assay, GI50 = 4.73 μM.	19796956
RPMI8402	Cytotoxicity assay		4 days	Cytotoxic activity against human lymphoblast tumor cell line RPMI8402 after 4 days of treatment. IC50=0.57 μM	12747798
PC3	Cytotoxicity assay		72 hrs	Cytotoxicity against human PC3 cells after 72 hrs by alamar blue assay, IC50 = 0.004 μM.	21341674
LNCAP	Cytotoxicity assay		72 hrs	Cytotoxicity against human LNCAP cells after 72 hrs by alamar blue assay, IC50 = 0.009 μM.	21341674
MESSA	Cytotoxicity assay		72 hrs	Cytotoxicity against human MESSA cells after 72 hrs by alamar blue assay, IC50 = 0.01 μM.	21341674
H460	Cytotoxicity assay		72 hrs	Cytotoxicity against human H460 cells after 72 hrs by alamar blue assay, IC50 = 0.015 μM.	21341674
H69	Cytotoxicity assay		72 hrs	Cytotoxicity against human H69 cells after 72 hrs by alamar blue assay, IC50 = 0.022 μM.	21341674
MES-SA/Dx5	Cytotoxicity assay		72 hrs	Cytotoxicity against human MES-SA/Dx5 cells overexpressing MDR1 after 72 hrs by alamar blue assay, IC50 = 0.022 μM.	21341674
H460	Cytotoxicity assay		72 hrs	Cytotoxicity against human H460 cells after 72 hrs by alamar blue assay in presence of 40 mg/ml HSA, IC50 = 0.027 μM.	21341674
IGROV1	Cytotoxicity assay		72 hrs	Cytotoxicity against human IGROV1 cells after 72 hrs by alamar blue assay, IC50 = 0.03 μM.	21341674
SK-MEL-2	Cytotoxicity assay		72 hrs	Cytotoxicity against human SK-MEL-2 cells after 72 hrs by alamar blue assay, IC50 = 0.1 μM.	21341674
MALME-3M	Cytotoxicity assay		72 hrs	Cytotoxicity against human MALME-3M cells after 72 hrs by alamar blue assay, IC50 = 0.2 μM.	21341674
DU145	Cytotoxicity assay		72 hrs	Cytotoxicity against human DU145 cells after 72 hrs by alamar blue assay, IC50 = 0.2 μM.	21341674
HT-29	Cytotoxicity assay		72 hrs	Cytotoxicity against human HT-29 cells after 72 hrs by alamar blue assay, IC50 = 0.22 μM.	21341674
H69AR	Cytotoxicity assay		72 hrs	Cytotoxicity against human H69AR cells overexpressing MDR1 after 72 hrs by alamar blue assay, IC50 = 0.25 μM.	21341674
HEK293	Inhibition of human		1.5 mins	Inhibition of human MATE1-mediated [14]-metformin uptake expressed in HEK293 cells after 1.5 mins by scintillation counting analysis, IC50 = 2.1 μM.	23241029
HEK293	Inhibition of human		3 mins	Inhibition of human OCT2-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay, IC50 = 2.7 μM.	23241029
MDCK2	Inhibition of human		5 mins	Inhibition of human MATE1-mediated [14]-metformin uptake expressed in polarized MDCK2 cells after 5 mins by liquid scintillation counting analysis, IC50 = 4.3 μM.	23241029
HEK293	Inhibition of human		1.5 mins	Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay, IC50 = 7.9 μM.	23241029
HEK293	Inhibition of human		3 mins	Inhibition of human OCT1-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay, IC50 = 20.8 μM.	23241029
H3347	Cytotoxicity assay		72 hrs	Cytotoxicity against human H3347 cells assessed as growth inhibition after 72 hrs by Alamar Blue assay, IC50 = 7.53 μM.	24583355
DLD1	Cytotoxicity assay		72 hrs	Cytotoxicity against human DLD1 cells assessed as growth inhibition after 72 hrs by Alamar Blue assay, IC50 = 25.1 μM.	24583355
DU145	Cytotoxicity assay		72 hrs	Cytotoxicity against human DU145 cells after 72 hrs by SRB assay, IC50 = 9.3 μM.	25003995
A549	Cytotoxicity assay		72 hrs	Cytotoxicity against human A549 cells after 72 hrs by SRB assay, IC50 = 9.5 μM.	25003995
KB	Cytotoxicity assay		72 hrs	Cytotoxicity against human KB cells after 72 hrs by SRB assay, IC50 = 9.8 μM.	25003995
MDA-MB-435	Cytotoxicity assay		72 hrs	Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay, IC50 = 6.3 μM.	26226379
HCT116	Cytotoxicity assay		72 hrs	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay, IC50 = 18.6 μM.	26226379
A549	Cytotoxicity assay		72 hrs	Cytotoxicity against human A549 cells after 72 hrs by MTT assay, IC50 = 20.1 μM.	26226379
HCT116	Antiproliferative assay		24 to 72 hrs	Antiproliferative activity against human HCT116 cells after 24 to 72 hrs by SRB assay, IC50 = 2 μM.	26595875
RKO	Antiproliferative assay		24 to 72 hrs	Antiproliferative activity against human RKO cells after 24 to 72 hrs by SRB assay, IC50 = 6.2 μM.	26595875
HCT15	Antiproliferative assay		24 to 72 hrs	Antiproliferative activity against human HCT15 cells after 24 to 72 hrs by SRB assay, IC50 = 8.5 μM.	26595875
SW480	Antiproliferative assay		24 to 72 hrs	Antiproliferative activity against human SW480 cells after 24 to 72 hrs by SRB assay, IC50 = 12.3 μM.	26595875
PC3	Antiproliferative assay		72 hrs	Antiproliferative activity against human PC3 cells assessed as cellular DNA content after 72 hrs by CyQUANT NF fluorescence assay, IC50 = 0.8 μM.	26731300
MCF7	Antiproliferative assay		96 hrs	Antiproliferative activity against human MCF7 cells assessed as cellular DNA content after 96 hrs by CyQUANT NF fluorescence assay, IC50 = 0.9 μM.	26731300
T84	Antiproliferative assay		96 hrs	Antiproliferative activity against human T84 cells assessed as cellular DNA content after 96 hrs by CyQUANT NF fluorescence assay, IC50 = 1.2 μM.	26731300
HT-29	Antiproliferative assay		72 hrs	Antiproliferative activity against human HT-29 cells assessed as cellular DNA content after 72 hrs by CyQUANT NF fluorescence assay, IC50 = 1.9 μM.	26731300
MCF7	Cytotoxicity assay		24 hrs	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTS assay, IC50 = 0.5 μM.	26841168
A549	Cytotoxicity assay		24 hrs	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 24 hrs by MTS assay, IC50 = 0.8 μM.	26841168
HepG2	Cytotoxicity assay		24 hrs	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTS assay, IC50 = 0.9 μM.	26841168
SW480	Cytotoxicity assay		24 hrs	Cytotoxicity against human SW480 cells assessed as reduction in cell viability after 24 hrs by MTS assay, IC50 = 1.4 μM.	26841168
A549	Cytotoxicity assay		72 hrs	Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B colorimetric assay, IC50 = 9.48 μM.	26994847
KB	Cytotoxicity assay		72 hrs	Cytotoxicity against human KB cells after 72 hrs by sulforhodamine B colorimetric assay, IC50 = 9.828 μM.	26994847
KB	Cytotoxicity assay		72 hrs	Cytotoxicity against human KB cells after 72 hrs by sulforhodamine B assay, IC50 = 7.99 μM.	28285912
A549	Cytotoxicity assay		72 hrs	Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay, IC50 = 8.3 μM.	28285912
MCF7	Cytotoxicity assay		72 hrs	Cytotoxicity against human MCF7 cells after 72 hrs by sulforhodamine B assay, IC50 = 11.3 μM.	28285912
MDA-MB-231	Cytotoxicity assay		72 hrs	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay, IC50 = 15.6 μM.	28285912
HCT116	Antiproliferative assay		72 hrs	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay, IC50 = 6.3 μM.	28351590
ZR-7530	Antiproliferative assay		72 hrs	Antiproliferative activity against human ZR-7530 cells after 72 hrs by MTT assay, IC50 = 18 μM.	28351590
A549	Antiproliferative assay		72 hrs	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay, IC50 = 20 μM.	28351590
KB	Cytotoxicity assay		72 hrs	Cytotoxicity against human KB cells after 72 hrs by SRB assay, IC50 = 7.99 μM.	28789891
A549	Cytotoxicity assay		72 hrs	Cytotoxicity against human A549 cells after 72 hrs by SRB assay, IC50 = 8.31 μM.	28789891
MCF7	Cytotoxicity assay		72 hrs	Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay, IC50 = 11.32 μM.	28789891
MDA-MB-231	Cytotoxicity assay		72 hrs	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by SRB assay, IC50 = 15.56 μM.	28789891
KB	Cytotoxicity assay		72 hrs	Cytotoxicity against human KB cells after 72 hrs by SRB assay, IC50 = 7.99 μM.	28927790
A549	Cytotoxicity assay		72 hrs	Cytotoxicity against human A549 cells after 72 hrs by SRB assay, IC50 = 8.3 μM.	28927790
MCF7	Cytotoxicity assay		72 hrs	Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay, IC50 = 11.3 μM.	28927790
MDA-MB-231	Cytotoxicity assay		72 hrs	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by SRB assay, IC50 = 15.6 μM.	28927790
Maver2	Antiproliferative assay		72 hrs	Antiproliferative activity against human Maver2 cells after 72 hrs by MTT assay, IC50 = 0.74 μM.	29150335
NB4	Antiproliferative assay		72 hrs	Antiproliferative activity against human NB4 cells after 72 hrs by MTT assay, IC50 = 1 μM.	29150335
Capan1	Antiproliferative assay		72 hrs	Antiproliferative activity against human Capan1 cells after 72 hrs by SRB assay, IC50 = 1.5 μM.	29150335
NCI-H460	Antiproliferative assay		72 hrs	Antiproliferative activity against human NCI-H460 cells after 72 hrs by SRB assay, IC50 = 2.4 μM.	29150335
DU145	Antiproliferative assay		72 hrs	Antiproliferative activity against human DU145 cells after 72 hrs by SRB assay, IC50 = 2.8 μM.	29150335
A2780	Antiproliferative assay		72 hrs	Antiproliferative activity against human A2780 cells after 72 hrs by SRB assay, IC50 = 3.8 μM.	29150335
HepG2	Antiproliferative assay		72 hrs	Antiproliferative activity against human HepG2 cells after 72 hrs by SRB assay, IC50 = 4 μM.	29150335
A431	Antiproliferative assay		72 hrs	Antiproliferative activity against human A431 cells after 72 hrs by SRB assay, IC50 = 4.1 μM.	29150335
U2932	Antiproliferative assay		72 hrs	Antiproliferative activity against human U2932 cells after 72 hrs by MTT assay, IC50 = 4.4 μM.	29150335
HT-29	Antiproliferative assay		72 hrs	Antiproliferative activity against human HT-29 cells after 72 hrs by SRB assay, IC50 = 4.8 μM.	29150335
HeLa	Antiproliferative assay		72 hrs	Antiproliferative activity against human HeLa cells after 72 hrs by SRB assay, IC50 = 5.8 μM.	29150335
A2780/DX	Antiproliferative assay		72 hrs	Antiproliferative activity against human A2780/DX cells after 72 hrs by SRB assay, IC50 = 20.1 μM.	29150335
HCT116	Antiproliferative assay		72 hrs	Antiproliferative activity against human HCT116 cells after 72 hrs by SRB assay, IC50 = 1.63347 μM.	30115492
A549	Antiproliferative assay		72 hrs	Antiproliferative activity against human A549 cells after 72 hrs by SRB assay, IC50 = 1.88093 μM.	30115492
KBV1	Cytotoxicity assay			Cytotoxicity against human KBV1 cells by MTT method, IC50 = 40 μM.	18771930
KBH5.0	Cytotoxicity assay			Cytotoxicity against human KBH5.0 cells by MTT method, IC50 = 7.4 μM.	18771930
KB3-1	Cytotoxicity assay			Cytotoxicity against human KB3-1 cells by MTT method, IC50 = 0.68 μM.	18771930
NCI60	Growth inhibition assay			Growth inhibition of human NCI60 cells by SBR assay, GI50 = 14.1254 μM.	21035334
DU145	Cytotoxicity assay			Cytotoxicity against human DU145 cells by SRB assay, IC50 = 9.3 μM.	23102893
A549	Cytotoxicity assay			Cytotoxicity against human A549 cells by SRB assay, IC50 = 9.48 μM.	23102893
KB	Cytotoxicity assay			Cytotoxicity against human KB cells by SRB assay, IC50 = 9.83 μM.	23102893
colon cancer cells	Cytotoxicity assay			Compound was tested in vitro for cytotoxicity against HCT116, human colon cancer cells (taxol-resistant) at a drug concentration producing 50% inhibition of colony formation, ID50 = 0.54 μM.	11965362
TC32	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	29435139
A673	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	29435139
DAOY	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	29435139
Saos-2	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	29435139
BT-37	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	29435139
RD	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	29435139
BT-12	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	29435139
MG 63 (6-TG R)	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	29435139
NB1643	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	29435139
OHS-50	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	29435139
LAN-5	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells	29435139
NB-EBc1	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells	29435139
A673	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)	29435139
BT-37	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells	29435139
MG 63 (6-TG R)	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells	29435139
Rh30	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells	29435139
OHS-50	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells	29435139
SK-N-SH	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for SK-N-SH cells	29435139
Rh41	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells	29435139
TC32	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for TC32 cells	29435139
MG 63 (6-TG R)	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for MG 63 (6-TG R) cells	29435139
SJ-GBM2	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	29435139
SK-N-MC	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	29435139
NB-EBc1	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	29435139
LAN-5	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	29435139
Rh18	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	29435139
NB1643	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells	29435139
SK-N-MC	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells	29435139
TC32	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells	29435139
Rh18	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells	29435139
Saos-2	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells	29435139
SJ-GBM2	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for SJ-GBM2 cells	29435139
他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

生物活性

製品説明

特性

Irinotecan is a prodrug that is used to treat metastatic colorectal cancer.

Targets

Topo I ^[1]

In Vitro
In vitro	Irinotecan is activated to SN-38 by carboxylesterases to become able to interact with its target, topoisomerase I. Irinotecan induces similar amounts of cleavable complexes at its IC50 in LoVo cells and HT-29 cell lines. SN-38 induces a concentration-dependent formation of cleavable complexes, which is not significantly different in LoVo cells and HT-29 cell lines. Cell accumulation of Irinotecan is markedly different, reaching consistently higher levels in HT-29 cells than in LoVo cells. ^[1] The lactone E-ring of Irinotecan and SN-38 hydrolyses reversibly in aqueous solutions, and the interconversion between the lactone and carboxylate forms is dependent on pH and temperature. Liver is primarily responsible for the activation of Irinotecan to SN-38. At equal concentrations of Irinotecan and SN-38 glucuronide, the rate of beta-glucuronidase-mediated SN-38 production is higher than that formed from Irinotecan in both tumour and normal tissue. ^[2] Irinotecan is also converted to SN-38 in intestines, plasma and tumor tissues. ^[3] Irinotecan is significantly more active in SCLC than in NSCLC cell lines, whereas no significant difference between histological types is observed with SN-38. ^[4]
細胞実験	細胞株	LoVo and HT-29 cells
	濃度	0 μM -100 μM
	反応時間	48 hours
	実験の流れ	Exponentially growing cells (LoVo and HT-29 cells) are seeded in 20 cm2 Petri dishes with an optimal cell number for each cell line (2 × 104 for LoVo cells, 105 for HT-29 cells). They are treated 2 days later with increasing concentrations of Irinotecan or SN-38 for one cell doubling time (24 hours for LoVo cells, 40 hours for HT-29 cells). After washing with 0.15 M NaCl, the cells are further grown for two doubling times in normal medium, detached from the support with trypsin-EDTA and counted in a hemocytometer. The IC50 values are then estimated as the Irinotecan or SN-38 concentrations responsible for 50% growth inhibition as compared with cells incubated without Irinotecan or SN-38.
実験結果図	Methods	Biomarkers	結果図	PMID
	Western blot	AMPK / p-AMPK / mTOR / p-mTOR / p70S6K / p-p70S6K NFκB p65 / phospho-NFκB p65 / NFκB p50 / IκBα / p27Kip1 TopI / pAKT / pMEK / pERK / p-p38 MAPK / pJNK2		25973791
	Immunofluorescence	NFκB		22206574
	Growth inhibition assay	Cell viability		25973791

In Vivo
In Vivo	In COLO 320 xenografts, Irinotecan induces a maximum growth inhibition of 92%. ^[5] A single dose of Irinotecan significantly increases amounts of topoisomerase I covalently bound to DNA in stomach, duodenum, colon and liver. Concomitantly, the Irinotecan-treated group shows significantly higher amounts of DNA strand breaks in colon mucosa cells compared to the control group. ^[6]
動物実験	動物モデル	Female nude mice with COLO 320 and WiDr xenografts.
	投与量	20 mg/kg
	投与経路	Intraperitoneal injection

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
臨床試験 (data from https://clinicaltrials.gov, updated on 2024-05-22)
NCT05854498	Recruiting	Metastatic Colorectal Cancer	University of Wisconsin Madison\|Ipsen	October 13 2023	Phase 2
NCT05732129	Not yet recruiting	Homologous Recombination Deficiency Alterations Metastatic Colorectal Cancer	Fudan University	March 1 2023	Phase 2
NCT05731518	Recruiting	Small Cell Lung Cancer	Biocity Biopharmaceutics Co. Ltd.	February 23 2023	Phase 1\|Phase 2
NCT06003998	Recruiting	Colorectal Cancer\|Peritoneal Metastases	Catharina Ziekenhuis Eindhoven	December 27 2022	Phase 2
NCT05277766	Recruiting	Peritoneal Carcinomatosis\|Peritoneal Metastases\|Colorectal Cancer\|Small Bowel Cancer\|Appendix Cancer\|Gastric Cancer\|Pancreatic Cancer\|Bile Duct Cancer	University Hospital Ghent\|Kom Op Tegen Kanker\|University Ghent	November 21 2022	Phase 1
NCT05379790	Recruiting	Gastric Cancer\|Peritoneal Metastases	Erasmus Medical Center	May 25 2022	Phase 1

参考
[1] Pavillard V, et al. Cancer Chemother Pharmacol. 2002, 49(4), 329-335. [2] Tobin P, et al. Br J Clin Pharmacol. 2006, 62(1), 122-129. [3] Shingyoji M, et al. Cancer Sci. 2004, 95(6), 537-540. [4] van Ark-Otte J, et al. Br J Cancer. 1998, 77(12), 2171-2176. [5] Jansen WJ, et al. Int J Cancer. 1997, 70(3):335-340. [6] Na YS, et al. Cancer Chemother Pharmacol. 2011, 68(2), 389-398. [7] Wagner LM, et al. Pediatr Blood Cancer. 2007, 48(2), 132-139. + 展開

参考

+ 展開

化学情報

分子量	677.18	化学式	C₃₃H₃₈N₄O₆.HCl.3H₂O
CAS No.	136572-09-3	SDF	Download Irinotecan HCl Trihydrate SDFをダウンロードする
Smiles	CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.O.O.O.Cl
保管	3年-20°C粉	溶液の保管冷凍と解凍の繰り返しを避けるため小分けにしてください	1年-80°Cin solvent
保管	3年-20°C粉	溶液の保管冷凍と解凍の繰り返しを避けるため小分けにしてください	１ケ月-20°Cin solvent

In vitro
Batch:

DMSO : 100 mg/mL ( (147.67 mM)；吸湿したDMSOは溶解度を減少させます。新しいDMSOをご使用ください。)

Water : Insoluble

Ethanol : Insoluble

モル濃度計算器

in vivo
Batch:

Add solvents to the product individually and in order.

投与溶液組成計算機

実験計算

モル濃度計算器

質量	濃度	体積	分子量
=	×	×

希釈計算器分子量計算器

投与溶液組成計算機(クリア溶液)

ステップ１：実験データを入力してください。（実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します）

投与量 mg/kg 動物平均体重 g 投与体積（動物毎）μL 動物数匹

ステップ２：投与溶媒の組成を入力してください。（ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください）

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

計算結果：

投与溶媒濃度： mg/ml;

DMSOストック溶液調製方法： mg 試薬を μL DMSOに溶解する（濃度 mg/mL, 注：濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。 )

投与溶媒調製方法：Take μL DMSOストック溶液に μL PEG300，を加え、完全溶解後μL Tween 80，を加えて完全溶解させた後 μL ddH₂O，を加え完全に溶解させます。

投与溶媒調製方法：μL DMSOストック溶液に μL Corn oil，を加え、完全溶解。

注意：１.ストック溶液に沈殿、混濁などがないことをご確認ください；
２.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

* 大学・企業名 大学・企業名を記入してください

* 名前 名前を記入してください

* 電子メール 電子メール・アドレスを記入してください 有効なメールアドレスを入力してください

電話番号

* 内容 お問い合わせ内容をご入力ください

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):